n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Intraocular Pressure in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bar-Yehuda, S; Cohen, S; Fishman, P | 1 |
Avni, I; Bakshi, E; Barequet, IS; Bristol, DR; Chetrit, N; Cohn, I; Farbstein, M; Fishman, P; Fishman, S; Garzozi, HJ; Harpaz, Z; Jacobson, KA; Kerns, WD; Litvin, G; Sartani, G; Segev, F; Silverman, MH; Tomkins, O; Varssano, D; Yehuda, SB; Zadok, D | 1 |
Avila, MY; Civan, MM; Stone, RA | 1 |
1 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Intraocular Pressure
Article | Year |
---|---|
Targeting the A3 adenosine receptor for glaucoma treatment (review).
Topics: Adenosine; Adenosine A3 Receptor Agonists; Anti-Inflammatory Agents; Apoptosis; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Receptor, Adenosine A3; Retinal Ganglion Cells | 2013 |
1 trial(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Intraocular Pressure
Article | Year |
---|---|
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Administration, Oral; Cornea; Double-Blind Method; Dry Eye Syndromes; Electrocardiography; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Middle Aged; Tears; Treatment Outcome | 2010 |
1 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Intraocular Pressure
Article | Year |
---|---|
Knockout of A3 adenosine receptors reduces mouse intraocular pressure.
Topics: Adenosine; Administration, Topical; Animals; Dihydropyridines; Intraocular Pressure; Mice; Mice, Inbred C57BL; Mice, Knockout; Ophthalmic Solutions; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A3; Receptors, Purinergic P1 | 2002 |